NCT00996333 - Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Gemcitabine, Docetaxel, Capecitabine

"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."

Trial Locations (1)

10032

Columbia University Medical Center, New York